Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 5, 2016

Primary Completion Date

March 30, 2019

Study Completion Date

March 30, 2019

Conditions
Obstructive Sleep ApneaNon-alcoholic Fatty Liver Disease
Interventions
DEVICE

Continuous positive airway pressure (CPAP)

Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.

Trial Locations (1)

Unknown

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT02728765 - Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter